This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reni, M. Articles by Villa, E. Search for Related Content PubMed PubMed Citation Articles by Reni, M. Articles by Villa, E. Social Bookmarking                            What's this?

Definitive Results of a Phase II Trial of Cisplatin, Epirubicin, Continuous-Infusion Fluorouracil, and Gemcitabine in Stage IV Pancreatic Adenocarcinoma

From the Departments of Radiochemotherapy, Radiology, and Surgery, and Unit of Epidemiology and Medical Statistics, San Raffaele H. Scientific Institution, Milan, Italy.

Address reprint requests to Michele Reni, MD, Department of Radiochemotherapy, San Raffaele H. Scientific Institute, Via Olgettina 60, 20132 Milan, Italy; email: reni.michele{at}hsr.it

PURPOSE: To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma.

PATIENTS AND METHODS: Patients 70 years, with no prior chemotherapy and with bidimensionally measurable stage IV pancreatic adenocarcinoma, Eastern Cooperative Oncology Group performance status 2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or Karnofsky performance status between 50 and 70. Treatment consisted of 40 mg/m² each of cisplatin and epirubicin day 1, gemcitabine 600 mg/m² on days 1 and 8 every 4 weeks, and fluorouracil 200 mg/m²/d as a protracted venous infusion.

RESULTS: Between April 1997 and April 1999, 49 patients from a single institution were eligible for the study. Altogether, 203 cycles (median, four cycles) of PEF-G were delivered. The objective response rate was 58% in 43 assessable patients and 51% in the intent-to-treat population. Fourteen patients had stable disease. Grade 3 or 4 World Health Organization neutropenia occurred in 51% of cycles, thrombocytopenia in 28%, anemia in 7%, stomatitis in 5%, and diarrhea, and nausea, and vomiting in 2%. The median duration of response was 8.5 months. The median time to tumor progression was 7.5 months. The median survival was 11 months in the assessable population and 10 months in the intent-to-treat population. Clinical benefit was achieved in 22 (78%) of 28 assessable patients.

CONCLUSION: PEF-G is a well-tolerated and safe regimen; it obtained a very high rate of durable responses and deserves further evaluation in a phase III trial.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. BAKSHANDEH-BATH, A. S. STOLTZ, N. HOMANN, T. WAGNER, S. STOLTING, and S. O. PETERS Preclinical and Clinical Aspects of Carboplatin and Gemcitabine Combined with Whole-body Hyperthermia for Pancreatic Adenocarcinoma Anticancer Res, August 1, 2009; 29(8): 3069 - 3077. [Abstract] [Full Text] [PDF]

				F. Huguet, T. Andre, P. Hammel, P. Artru, J. Balosso, F. Selle, E. Deniaud-Alexandre, P. Ruszniewski, E. Touboul, R. Labianca, et al. Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies J. Clin. Oncol., January 20, 2007; 25(3): 326 - 331. [Abstract] [Full Text] [PDF]

				A. Wagner, P Buechner-Steudel, A Wein, H Schmalenberg, U Lindig, M Moehler, R Behrens, G Kleber, O Kuss, and W. Fleig Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Ann. Onc., January 1, 2007; 18(1): 82 - 87. [Abstract] [Full Text] [PDF]

				R. D. Petty, M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, and M. Koruth A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity Ann. Onc., July 1, 2003; 14(7): 1100 - 1105. [Abstract] [Full Text] [PDF]

				J. P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D. D. Stocken, D. M. Tait, J. A. Dunn, C. Dervenis, F. Lacaine, H. Hickey, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann. Onc., May 1, 2003; 14(5): 675 - 692. [Abstract] [Full Text] [PDF]

				S. McKenna and M. Eatock The Medical Management of Pancreatic Cancer: A Review Oncologist, April 1, 2003; 8(2): 149 - 160. [Abstract] [Full Text] [PDF]

				F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care Oncologist, February 1, 2003; 8(1): 18 - 34. [Abstract] [Full Text] [PDF]

				W. Scheithauer, B. Schull, H. Ulrich-Pur, K. Schmid, M. Raderer, K. Haider, W. Kwasny, D. Depisch, B. Schneeweiss, F. Lang, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann. Onc., January 1, 2003; 14(1): 97 - 104. [Abstract] [Full Text] [PDF]

				J. Feliu, R. Mel, P. Borrega, L. Lopez Gomez, P. Escudero, J. Dorta, J. Castro, S. E. Vazquez-Estevez, M. Bolanos, E. Espinosa, et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas Ann. Onc., November 1, 2002; 13(11): 1756 - 1762. [Abstract] [Full Text] [PDF]

				C. Louvet, T. Andre, G. Lledo, P. Hammel, H. Bleiberg, C. Bouleuc, E. Gamelin, M. Flesch, E. Cvitkovic, and A. de Gramont Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study J. Clin. Oncol., March 15, 2002; 20(6): 1512 - 1518. [Abstract] [Full Text] [PDF]